| Primary information |
|---|
| sequence ID | Seq_7017 |
| Peptide sequence | SEMVVAGKLQ |
| CancerPDF_ID | CancerPDF_ID808, CancerPDF_ID8613, CancerPDF_ID9817, CancerPDF_ID12173, CancerPDF_ID12664, |
| PMID | 19795908,26705257,21533267,26992070,26992070 |
| Protein Name | Inter-alpha-trypsin inhibitor heavy chain H4,Inter- trypsin inhibitor heavy chain H4 (ITIH4) precursor,Inter-alpha-trypsin inhibitor heavy chain H4,ITIH4 protein,ITIH4 protein |
| UniprotKB Entry Name | ITIH4_HUMAN,ITIH4_HUMAN,ITIH4_HUMAN,ITIH4_HUMAN,ITIH4_HUMAN |
| Fluid | Plasma,Serum,Serum,Serum,Serum |
| M/Z | 531.28,1061.09,531.28,1060.5587,NA |
| Charge | 2,NA,2,NA,NA |
| Mass (in Da) | NA,NA,NA,1061.568407,1077.562181 |
| fdr | NA,NA,NA,NA,NA |
| Profiling Technique | LC-MS,MALDI-TOF,LC-MS,LC-MS,LC-MS |
| Peptide Identification technique | MALDI-TOF/TOF,LC-ESI-MS/MS,LC/MS/MS,LC-MS/MS,LC-MS/MS |
| Quantification Technique | LC-MRM (multiple reaction monitoring),NA,Multiple Reaction Monitoring,NA,NA |
| Labelled/Label Free | Labelled,Label Free,Label Free,Label Free,Label Free |
| FDR | less than 7%,NA,1.49,FDR 1 %,FDR 1 % |
| CancerPDF_ID | CancerPDF_ID808, CancerPDF_ID8613, CancerPDF_ID9817, CancerPDF_ID12173, CancerPDF_ID12664, |
| p-Value | NA,1.00E-06,NA,NA,NA |
| Software | FlexAnalysis 3.0 and Biotools 3.0 software,ClinProTools,MASCOT,SEQUEST and Maxquant,"Maxquant,Proteome Discoverer" |
| Length | 10,10,10,10,10 |
| Cancer Type | Ductal adenocarcinoma of the pancreas (DAP),Breast cancer,Lung adenocarcinoma,Melanoma,Melanoma |
| Database | NCBI refseq Protein Database,Uniprot protein sequence Database,Swissprot Database (57.4),SwissProt Database,SwissProt Database |
| Modification | NA,NA,NA,NA,NA |
| Number of Patients | "42 normal, 28 patients",96 Breast Cancer patients and 64 healthy controls,62 lung adenocarcinoma and 30 healthy control,8 cancer samples and 4 healthy samples,8 cancer samples and 4 healthy samples |
| Regulation | NA,Upregulated in cancer as compare to normal control with fold change of 1.6,"Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal","Present in 8 cancer samples out of 8 cancer samples. ,Present in 4 healthy samples out of 4 healthy samples.","Present in 8 cancer samples out of 8 cancer samples. ,Present in 4 healthy samples out of 4 healthy samples." |
| Validation | NA,NA,MRM-based validation of 19 candidates,na,NA |
| Sensitivity | NA,0.7904,NA,NA,NA |
| Specificity | NA,82.18,NA,NA,NA |
| Accuracy | NA,NA,NA,NA,NA |
| Peptide Atlas | NA |
| IEDB | |